{"id":"W4415943874","doi":"10.1016/j.esmoop.2025.105833","title":"Retreatment, rechallenge, and escalation with subsequent immune checkpoint inhibitor therapies across cancers after initial failure","year":2025,"lang":"en","type":"review","venue":"ESMO Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Bristol-Myers Squibb","keywords":"Clinical trial; Nivolumab; Immunotherapy; Immune checkpoint; Cancer; PD-L1; Immune system; Antibody therapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003975858,0.0005217225,0.001552349,0.0001080554,0.0001427116,0.0001871973,0.0002248187,0.0003834444,0.0003413266],"category_scores_gemma":[0.00001582551,0.0003372625,0.000282649,0.000329087,0.0001927817,0.0001816029,0.0002035958,0.0004049673,0.000008382388],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008121867,"about_ca_system_score_gemma":0.001037796,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001741799,"about_ca_topic_score_gemma":0.002815585,"domain_scores_codex":[0.9981038,0.0001403259,0.000599999,0.0005987043,0.0002282596,0.0003289391],"domain_scores_gemma":[0.9988785,0.00007450919,0.0003222067,0.000557568,0.00008053451,0.00008663587],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.002934286,0.00007812447,0.00009620208,0.00794343,0.001875644,0.0001170676,0.001006941,3.790073e-8,0.000003425007,0.000009936078,0.0003275031,0.9856074],"study_design_scores_gemma":[0.003325155,0.0006504612,0.0009288673,0.04507222,0.0008920062,0.0001223079,0.0003410981,2.418085e-7,0.00007872174,0.00001310834,0.9481632,0.0004126842],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0005995678,0.9930403,0.000005943344,0.0006202601,0.000230887,0.003387704,0.0001527936,0.00004006333,0.001922479],"genre_scores_gemma":[0.001490732,0.9933227,0.0003360594,0.0001463355,0.0002038273,0.001267141,0.0003489997,0.00006433469,0.002819869],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9851947,"threshold_uncertainty_score":0.9999079,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04539532483745746,"score_gpt":0.377661229121693,"score_spread":0.3322659042842356,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}